Avrobio is a leading brand that specializes in lentiviral-based gene therapy. Their mission is to halt or reverse genetic diseases with a single dose of gene therapy, allowing individuals with genetic diseases to live longer and free from disease progression, symptoms, and the burden of chronic treatment regimens. Avrobio's approach is highly personalized, as they use the patient's own stem cells to develop their investigational gene therapies.

They focus on treating serious lysosomal disorders and have developed a state-of-the-art platform called plato® to optimize gene therapies. Avrobio keeps up with the latest developments in gene therapy, and their expert team shares valuable insights and perspectives through their blog. They are dedicated to innovation, collaboration, and dedication, and they strive to bring pioneering therapies to individuals living with genetic diseases.

With clinical trials conducted in four countries and four disease indications in their pipeline, Avrobio's goal is to provide individuals with genetic diseases with freedom for life